Publications by authors named "W Abramowitz"
Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Clin Pharmacol Ther
January 2006
Article Synopsis
- The study aimed to assess how Alzheimer's treatment memantine is processed by the body in people with different levels of kidney function.
- Thirty-two participants were grouped based on their kidney function, and after taking a single dose of memantine, their drug absorption and safety were measured.
- Results showed that while those with normal and mild kidney issues had similar drug levels, those with moderate and severe kidney impairment had significantly higher drug concentrations, suggesting that a lower dose of memantine (5 mg twice daily) is necessary for severe impairment while keeping the standard dose for mild to moderate cases.
Article Synopsis
- The study examined the interaction between memantine (used for Alzheimer's) and glyburide/metformin (for type 2 diabetes) in healthy adults.
- Participants received memantine alone, followed by glyburide/metformin, and then both together to see if there were any combined effects.
- Results showed no significant interactions or adverse effects impacting safety between memantine and glyburide/metformin, although some participants experienced mild dizziness.
Aims: Dexloxiglumide is a new CCK(1) receptor antagonist under investigation for treatment of functional gastrointestinal disorders and is metabolized by CYP3A4 and CYP2C9. The objectives of these two separate randomized, two-period, two-treatment crossover studies were to investigate the effects of steady-state ketoconazole, a model CYP3A4 inhibitor (Study 1), and steady-state fluconazole, a model CYP2C9 inhibitor (Study 2), on the pharmacokinetics of dexloxiglumide in healthy subjects.
Methods: Plasma samples were analysed for dexloxiglumide and its primary metabolites: O-demethyl dexloxiglumide (ODM; Study 1 and 2) and dexloxiglumide carboxylic acid (DCA; Study 2).
The single-dose pharmacokinetics of the novel CCK1 receptor antagonist, dexloxiglumide, are not influenced by age and gender.
Int J Clin Pharmacol Ther
September 2005
Objective: The effects of age and gender on the single-dose pharmacokinetics of dexloxiglumide, a selective cholecystokinin (CCK1-subtype) receptor antagonist, were assessed in healthy young and elderly male and female subjects.
Methods: In total, 24 males and 24 females (12 young and 12 elderly subjects per gender group) received a single oral dose of 200 mg dexloxiglumide under fasted conditions. Mean (range) ages were 23.
Background: As part of ongoing studies to evaluate the analgesic efficacy and pharmacokinetic properties of combination oxycodone plus ibuprofen in the treatment of moderate to severe acute pain, 2 pharmacokinetic studies were conducted.
Objectives: The goals of these studies were to compare the pharmacokinetic properties of monotherapy with oxycodone or ibuprofen with those of a tablet formulation of these 2 agents combined (study A), and to determine whether the absorption of the individual agents when given in the combination tablet was affected by the concomitant ingestion of food (study B).
Methods: Study A was a single-center, open-label, randomized, single-dose, 3-period, 3-way, crossover study.